CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights steady revenue growth and strong adoption of CapsoCam Plus, but concerns about financial sustainability and product development risks temper the positive outlook. The Q&A session reveals ongoing product development with potential delays due to summer vacations. Despite raising additional funds, high operating expenses and unclear timelines for FDA submissions are concerns. The overall sentiment is neutral, as strong financial metrics are offset by uncertainties in product development and financial sustainability.
Key Financial Performance
Full Year Revenue Growth 15% year-over-year growth, driven by continued adoption of CapsoCam Plus across both new and existing customers.
New Account Generation 21% year-over-year growth, reflecting increased adoption of CapsoCam Plus.
Patients Imaged with CapsoCam Plus 161,000 patients as of December 31, 2025, showcasing a growing installed base and strong physician engagement.
Fourth Quarter Revenue $3.9 million, reflecting 13% growth compared to the fourth quarter of 2024, driven by an increase in the number of CapsoCam Plus capsules sold.
Gross Profit $2 million, an increase of $200,000 or 13% compared to the fourth quarter of 2024, consistent with scaling expectations.
Gross Margin 50% for the quarter, consistent with expectations as the company scales.
Operating Expenses $9.4 million, a $3.1 million increase from the fourth quarter of 2024, primarily due to development expenses for new CMOS image sensors, investment in the Colon clinical study, and public company expenses.
Cash and Equivalents $10.1 million at year-end, with an additional $14 million raised through a private placement post-year-end to support commercial expansion, R&D, and pipeline programs.
Fourth Quarter Patient Utilization 9,400 patients utilized CapsoCam Plus, representing 12% year-over-year growth, driven by increasing physician awareness and ease of integration into workflows.
New Account Growth in Fourth Quarter 16% year-over-year growth, reflecting continued physician adoption of CapsoCam Plus for small bowel screening.
Hospital System Customers 87% increase in the number of hospital system customers in the fourth quarter compared to the same period last year, driven by increased penetration in GI clinics and mega GI groups.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CapsoCam Plus: Achieved 15% year-over-year revenue growth and 21% new account generation. Over 161,000 patients imaged as of December 31, 2025. Features include 360-degree panoramic imaging, cloud-based workflow, and AI capabilities.
AI-assisted reading module: Submitted 510(k) application for AI-assisted reading module to enhance lesion detection and streamline physician review.
CapsoCam Colon Gen 2: Refined development strategy based on FDA feedback. Focused on improved imaging, expanded field of view, and enhanced AI functionality. Over 400 patients enrolled in pivotal study. 510(k) application expected in Q3 2026.
CapsoCam UGI program: Initiating a clinical study in Q2 2026 to establish diagnostic criteria for pancreatic cancer detection. Study to enroll 60-90 patients.
U.S. and international market expansion: Adoption of CapsoCam Plus expanded across U.S. and international markets. Increased penetration in GI clinics, mega GI groups, and hospital systems. Hospital system customers increased by 87% in Q4 2025.
Reimbursement and telemedicine: Expanded reimbursement support and adoption in telemedicine. Approved for pediatric patients over age 2 and remote capsule ingestion.
Financial performance: Q4 2025 revenue was $3.9 million, a 13% year-over-year growth. Gross profit increased by $200,000 to $2 million. Operating expenses rose due to R&D investments and public company costs.
Private placement funding: Raised $14 million through private placement to support R&D, commercial expansion, and pipeline programs.
Pipeline strategy: Focused on advancing AI-enabled platforms and next-generation products like CapsoCam Colon Gen 2. Prioritizing innovation and clinical development.
Pancreatic cancer initiative: Developing a noninvasive screening approach for pancreatic cancer. Engaged with FDA and planning clinical studies to establish diagnostic criteria.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The company faces regulatory hurdles, including the need for FDA approval for its CapsoCam Colon Gen 2 and pancreatic cancer screening initiatives. Feedback from the FDA has necessitated adjustments to development strategies, which could delay product launches.
Development Costs: Increased operating expenses, particularly related to the development of new CMOS image sensors and clinical studies for CapsoCam Colon and pancreatic cancer screening, are impacting financial performance.
Market Competition: The company is being evaluated alongside incumbent solutions in hospital systems and group purchasing organizations, indicating competitive pressures in the market.
Financial Sustainability: Despite raising $14 million in private placement, the company ended the year with only $10.1 million in cash and equivalents, raising concerns about long-term financial sustainability given its high operating expenses.
Product Development Risks: The shift to focus on CapsoCam Colon Gen 2 and the need to refine diagnostic criteria for pancreatic cancer screening introduce risks related to product development timelines and successful execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
AI-assisted reading module: CapsoVision submitted a 510(k) application for an AI-assisted reading module designed to enhance lesion detection and streamline physician review. This is expected to expand the clinical and economic value of their core platform.
CapsoCam Colon Gen 2: The company is focusing on accelerating the development of CapsoCam Colon Gen 2, incorporating improved imaging performance, expanded field of view, and enhanced AI functionality. A 510(k) application for this product is expected in Q3 2026.
Pancreatic cancer initiative: CapsoVision is developing a noninvasive screening approach for pancreatic cancer. A clinical study to establish diagnostic criteria is expected to begin in Q2 2026, enrolling 60-90 patients.
Financial strategy: The company raised $14 million in a private placement to support product innovation, clinical development, and commercial expansion.
Revenue growth: CapsoVision expects continued revenue growth driven by increasing adoption of CapsoCam Plus and expansion into new indications.
Commercial expansion: The company plans to leverage its existing sales infrastructure to support the launch of new products like CapsoCam Colon, creating cross-selling opportunities without significant incremental investment.
Regulatory advancements: CapsoVision is progressing regulatory pathways for CapsoCam Colon Gen 2 and the pancreatic cancer initiative, with key submissions and studies planned for 2026.
AI and cloud-based platform: The company aims to further develop its AI-enabled platform and cloud-based infrastructure to improve diagnostic accuracy and clinical efficiency.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What feedback has been received so far on the Gen 2 CapsoCam Colon efforts, and when can results of the study be expected?
A:The Gen 2 CapsoCam Colon has higher resolution, better image quality, and a larger field of view for improved detection. Enrollment is progressing well, with over 500 patients enrolled out of the target 800. The company is on track to file the FDA submission by the end of Q3, with no delays reported.
Q:What criteria are being considered for the Breakthrough Designation application for pancreatic cancer detection, and can the 90-patient study results be used for the FDA application?
A:The criteria include a scoring system based on features like papilla abnormality, tumor growth, and other disease-related variables such as gender and age. The scoring system is built using a mathematical model and will be validated with a separate population. This system is critical for the Breakthrough Designation application, which prioritizes FDA review. Additional validation studies may be required for external populations.
Q:What is the current status of the Colon Cam development timeline, including patient recruitment and site numbers?
A:For Gen 2, the target is 800 patients, with over 500 enrolled so far across 11 sites in the U.S. Recruitment is progressing well, with close to 600 patients enrolled. However, summer vacations for doctors may impact the timeline slightly. Overall, the process is on track.
Q:What is the anticipated review time for the 510(k) submission, and when might the Gen 2 Colon Cam capsule be commercially available?
A:The FDA review is expected to take 6 months. If the submission is made by the end of Q3, clearance is anticipated by Q1 2027, with commercial availability expected in the second half of 2027.
Q:Review of Unclear Management Responses
A:Management avoided providing specific feedback from the 500+ enrolled patients in the Gen 2 CapsoCam Colon study and did not clarify when exactly the study results would be available. Additionally, while discussing the Breakthrough Designation application, the explanation of the scoring system and its validation process was somewhat vague and lacked detailed timelines or specific next steps.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
CapsoCam Colon
CapsoCam Plus
CapsoCam UGI
CapsoVision
FDA
Gen
President
ability
adoption CapsoCam
approach
cancer
capsule
closing
cloud
detection
development
end
expansion
expectation
feedback
foundation
hospital system
increase
investment
investor
market
momentum
need
number
opportunity
patient
period
physician
platform
program
screening
statement
study
term
today
value
CV Transcript
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call presents mixed signals: while there is optimism about new product developments and regulatory progress, there are notable concerns such as declining gross margins, increased operating expenses, and shipment timing issues. The Q&A session did not reveal any significant obstacles but highlighted uncertainties regarding revenue timing and clinical study timelines. These factors, coupled with stable revenue and no clear guidance changes, suggest a neutral stock price movement over the next two weeks.
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call highlights steady revenue growth and strong adoption of CapsoCam Plus, but concerns about financial sustainability and product development risks temper the positive outlook. The Q&A session reveals ongoing product development with potential delays due to summer vacations. Despite raising additional funds, high operating expenses and unclear timelines for FDA submissions are concerns. The overall sentiment is neutral, as strong financial metrics are offset by uncertainties in product development and financial sustainability.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
